DelveInsight reports that the Amyotrophic Lateral Sclerosis (ALS) pipeline involves over 75 key companies actively developing more than 80 investigational therapies.
Amyotrophic Lateral Sclerosis Overview:
Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrig’s disease, is a progressive neurodegenerative condition that targets motor neurons. Its development involves both hereditary and sporadic factors, although no single cause has been definitively established. ALS affects both upper and lower motor neurons, often beginning with lower motor neuron degeneration in the proximal limbs, and gradually progresses to paralysis, ultimately resulting in death.
While several mechanisms have been suggested, the precise cause of sporadic ALS remains unclear. Contributing factors may include disruptions in RNA processing that promote prion-like aggregation, mutations in the superoxide dismutase 1 (SOD1) gene causing free radical toxicity, inflammatory processes, and elevated glutamate levels. Familial ALS, a less common form, is frequently associated with genetic mutations—most notably the C9ORF72 repeat expansion and SOD1 mutations. Misfolded SOD1 proteins aggregate toxically, leading to cellular damage and apoptosis, with these mutations typically inherited in an autosomal dominant pattern.
Overall, ALS is a complex disorder with multiple contributing factors rather than a single origin, resulting in a multifactorial and heterogeneous pathogenesis.
Request for a detailed insights report on Amyotrophic Lateral Sclerosis pipeline insights
"Amyotrophic Lateral Sclerosis Pipeline Insight 2025" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Amyotrophic Lateral Sclerosis Therapeutics Market.
Key Takeaways from the Amyotrophic Lateral Sclerosis Pipeline Report
-
DelveInsight’s Amyotrophic Lateral Sclerosis pipeline report depicts a robust space with 75+ active players working to develop 80+ pipeline therapies for Amyotrophic Lateral Sclerosis treatment.
-
Key Amyotrophic Lateral Sclerosis companies such as AIonis Pharmaceuticals, 1ST Biotherapeutics, Scholar Rock, Revalesio, QurAlis Corporation, Sanofi, MediciNova, Helixmith, Verge Genomics, UCB, and others are evaluating new drugs for Amyotrophic Lateral Sclerosis to improve the treatment landscape.
-
Promising Amyotrophic Lateral Sclerosis pipeline therapies in various stages of development include MN-166, RNS60, VM202, QRL-201, and others.
-
Celosia Therapeutics, a biotech startup from Macquarie University, has secured funding to advance CTX-1000, a potential disease-modifying therapy targeting the TDP-43 protein implicated in ALS pathology. Preclinical studies have shown promise, and human trials are anticipated to commence by late 2025.
-
In April 2023, the FDA approved Qalsody for patients with ALS associated with mutations in the superoxide dismutase 1 (SOD1) gene. Qalsody is an antisense oligonucleotide designed to reduce the synthesis of the SOD1 protein, addressing a specific genetic subset of ALS. The approval was based on observed reductions in plasma neurofilament light (NfL), a biomarker indicative of neuronal injury and degeneration.
Amyotrophic Lateral Sclerosis Pipeline Analysis
The report provides insights into:
-
The report provides detailed insights into the key companies that are developing therapies in the Amyotrophic Lateral Sclerosis Market.
-
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Amyotrophic Lateral Sclerosis treatment.
-
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
-
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
-
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Amyotrophic Lateral Sclerosis market.
Download our free sample page report on Amyotrophic Lateral Sclerosis pipeline insights
Amyotrophic Lateral Sclerosis Emerging Drugs
-
MN-166: MediciNova
-
RNS60: Revalesio
-
VM202: Helixmith
-
QRL-201: QurAlis Corporation
Amyotrophic Lateral Sclerosis Companies
Over 75 leading companies are actively developing therapies for Amyotrophic Lateral Sclerosis (ALS), with MediciNova having the most advanced candidates currently in Phase II/III clinical trials.
DelveInsight’s report covers around 80+ products under different phases of clinical development like
-
Late stage products (Phase III)
-
Mid-stage products (Phase II)
-
Early-stage product (Phase I) along with the details of
-
Pre-clinical and Discovery stage candidates
-
Discontinued & Inactive candidates
Amyotrophic Lateral Sclerosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
-
Intravenous
-
Subcutaneous
-
Oral
-
Intramuscular
Amyotrophic Lateral Sclerosis Products have been categorized under various Molecule types such as
-
Monoclonal antibody
-
Small molecule
-
Peptide
Download Sample Pages to Get an in-depth Assessment of the Emerging Amyotrophic Lateral Sclerosis Therapies and Key Companies: Amyotrophic Lateral Sclerosis Clinical Trials and advancements
Amyotrophic Lateral Sclerosis Pipeline Therapeutic Assessment
• Amyotrophic Lateral Sclerosis Assessment by Product Type
• Amyotrophic Lateral Sclerosis By Stage
• Amyotrophic Lateral Sclerosis Assessment by Route of Administration
• Amyotrophic Lateral Sclerosis Assessment by Molecule Type
Download Amyotrophic Lateral Sclerosis Sample report to know in detail about the Amyotrophic Lateral Sclerosis treatment market @ Amyotrophic Lateral Sclerosis Therapeutic Assessment
Table of Content
1. Report Introduction
2. Executive Summary
3. Amyotrophic Lateral Sclerosis Current Treatment Patterns
4. Amyotrophic Lateral Sclerosis - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Amyotrophic Lateral Sclerosis Late-Stage Products (Phase-III)
7. Amyotrophic Lateral Sclerosis Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Amyotrophic Lateral Sclerosis Discontinued Products
13. Amyotrophic Lateral Sclerosis Product Profiles
14. Amyotrophic Lateral Sclerosis Key Companies
15. Amyotrophic Lateral Sclerosis Key Products
16. Dormant and Discontinued Products
17. Amyotrophic Lateral Sclerosis Unmet Needs
18. Amyotrophic Lateral Sclerosis Future Perspectives
19. Amyotrophic Lateral Sclerosis Analyst Review
20. Appendix
21. Report Methodology
Request the Sample PDF to Get Detailed Insights About the Amyotrophic Lateral Sclerosis Pipeline Reports Offerings
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
